AstraZeneca Resumes COVID-19 Vaccine Candidate Trial in South Africa
AstraZeneca (NYSE: AZN) continues to get back on its feet after clinical trials for its coronavirus vaccine candidate were halted. On Tuesday, South Africa's Department of Health said the company had resumed the part of the trials taking place in that country.
The news came over a week after the U.K. trial of AZD1222 was halted due to one participant developing a side effect (which was not specified). It also came three days after that study was given the green light to restart. That was granted after an independent committee overseeing the British trial informed that country's Medicines Health Regulatory Authority that it felt it was safe to relaunch the study.
Image source: Getty Images.
Source Fool.com
